Key Takeaways:
Eli Lilly & Co.'s Jaypirca (pirtobrutinib) received a positive opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use for adults with chronic lymphocytic leukemia across all lines of therapy, regardless of prior BTK inhibitor treatment.
"The strong efficacy and tolerability demonstrated in these trials underscores the clinical value pirtobrutinib may offer patients," Paolo Ghia, professor of medical oncology at Università Vita-Salute San Raffaele in Milan, said.
The opinion is based on data from two Phase 3 trials. BRUIN CLL-313 enrolled 282 treatment-naïve patients randomized to receive pirtobrutinib 200 milligrams once daily or chemoimmunotherapy. BRUIN CLL-314 enrolled 662 patients randomized to pirtobrutinib or ibrutinib 420 milligrams once daily, making it the first Phase 3 CLL trial to compare a non-covalent BTK inhibitor against a covalent one in the treatment-naïve setting. Results were presented at the American Society of Hematology annual meeting in December 2025 and published in the Journal of Clinical Oncology.
The application now goes to the European Commission for final action, with a decision expected within one to two months. If approved, the indication would cover newly diagnosed patients and those who have received prior therapy, including prior BTK inhibitors. Lilly has also submitted the data to the U.S. Food and Drug Administration, with a decision expected in the second half of 2026.
Jaypirca is a non-covalent BTK inhibitor that is 300 times more selective for BTK versus 98% of other kinases tested in preclinical studies. It is already approved in the U.S. for adults with relapsed or refractory CLL or small lymphocytic lymphoma after prior covalent BTK inhibitor treatment, and for relapsed or refractory mantle cell lymphoma after at least two lines of systemic therapy.
Chronic lymphocytic leukemia is one of the most common leukemias in adults, with roughly 100,000 new cases globally each year and an incidence of about 4.92 cases per 100,000 people annually in Europe.
The CHMP backing expands Jaypirca's potential addressable market in the European Union to include first-line CLL patients, a population that has not previously been eligible for the drug in the region. Investors will watch for the European Commission's final decision in the coming weeks and the FDA's ruling later this year, which together could establish pirtobrutinib as a standard-of-care option across all lines of CLL therapy.
This article is for informational purposes only and does not constitute investment advice.
